{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 40,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a structured layout to categorize updates into three main pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/9",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.22,
        "y": 0.38
      },
      "kind": "list",
      "text": "iNEST Phase 2 start; BNT161 Phase 1 start; SITC presentations; BNT111 FDA Orphan Designation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b316817-aebd-47c9-80a3-afe958e2fa61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.22,
        "y": 0.22
      },
      "kind": "list",
      "text": "Reported Q3 total revenues of €6.1 bn; Acquisition of PhagoMed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7cc3b18-1d19-4160-9615-701c9fb9d3de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.22,
        "y": 0.65
      },
      "kind": "list",
      "text": "Delivered >2 bn doses; 2.5 bn expected in 2021; U.S. pediatric purchase; BLA approval; Booster dose approvals; Label extension",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dff23096-b2b6-493b-a61d-2015f141f617",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Third Quarter 2021 Highlights",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b2a14bb-2564-4205-9371-56966bf88df5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "CPI R/R, checkpoint inhibitor resistant or refractory; As of November 2, 2021: includes doses shipped by collaboration partner Pfizer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b923b05-74c7-4a3f-a1b2-cf3ba2d5f4ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.1
      },
      "kind": "title",
      "text": "Strong Performance in the Third Quarter of 2021",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afd17335-ccbb-4103-8f8f-b2989b3be528",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "c8835ed1-dfeb-4ac3-b9ba-84cf21035a98",
      "evidence": "list/bullet: Delivered >2 bn doses; 2.5 bn expected in 2021; U.S. pediatric purchase; BLA approval; Booster dose approvals; Label extension",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "0825e738-34e2-4db3-9c23-a297914524f2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The presentation highlights BioNTech's strong performance and pipeline expansion",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "e3928016-4f85-43ef-b051-6dae022547eb",
      "evidence": "The presentation provides a clear logic chain of performance and pipeline growth",
      "position": 0,
      "objective": "To demonstrate BioNTech's strong performance and pipeline expansion",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}